R. Hector MacKay-Dunn, K.C.

Representative Work: Canadian Counsel to Mind Cure Health Inc. in its $147.5M business combination with LNG Energy Group; Canadian Counsel to Arbutus Biopharma Corporation in its US$286M At-the-Market equity program; Canadian Counsel to Canexia Health Inc., innovator in genomics-based cancer testing, in its merger with Imagia Cybernetics Inc.; Lead Counsel to Mind Cure Health Inc., a cutting edge metal health and wellness company in its CDN$23M Bought Deal Public Offer; Canadian Counsel to Arbutus Biopharma Corporation with respect to the sale of part of its royalty interest on future global net sales of ONPATTRO (patisiran), an RNA interference (RNAi) therapeutic to OMERS, the defined benefit pension plan for municipal employees based in the Province of Ontario, Canada.; Canadian Counsel to Arbutus Biopharma Corporation and the Arbutus Special Committee with respect to closing of a US$116 million Strategic Investment from Roivant Sciences; Counsel to the Special Committee of the Board of Directors of Pacific Insight Electronics Inc. in its sale to Methode Electronics; Canadian Counsel to Arbutus Biopharma Corporation and the Arbutus Special Committee in launching Genevant Sciences with industry-leading platform to develop a broad range of RNA Therapeutics for genetic diseases; Canadian Counsel to Tekmira Pharmaceuticals Corporation in a merger of equals with OnCore Biopharma, Inc. creating an industry-leading therapeutics solutions company focused on developing a cure for chronic hepatitis B virus; Amgen Inc., Biovail Laboratories International SRL and MedGenesis Therapeutix Inc. global license agreements and collaboration agreement between Biovail and MedGenesis and related equity investment by Amgen Inc. in MedGenesis, for development of GDNF for an undisclosed amount; Acquisition of Can Test Ltd., British Columbia's largest independent analytical laboratory business, for an undisclosed price, by Maxxam Analytics International Corporation, a company majority owned by OMERS Administration Corporation; US $915 million acquisition of Aspreva Pharmaceuticals Corporation, by Galenica Group under which Galenica, through a wholly-owned Canadian subsidiary, will acquire all of Aspreva's outstanding shares for cash